Catheter Ablation Versus Antiarrythmic Drugs for Atrial Fibrillation in China

• Status: Unknown status
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The mainstay of treatment for atrial fibrillation remains pharmacological;however,catheter ablation has increasingly been used over the last decades. The relative merits of each strategy have not been extensively studied. Our study was designed to determine if catheter ablation is a feasible option as first-line therapy for treating patients with symptomatic AF.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wuhan University
• Collaborators: Capital Medical University; Dalian Medical University; Guangdong General Hospital; Guangdong Provincial People's Hospital; Nanjing Medical University; Peking Union Medical College; Shanghai Chest Hospital; West China Hospital
• Treatments: Amiodarone; Calcium; Calcium Channel Blockers

Criteria

Inclusion Criteria:

• 1 Patients with symptomatic AF recorded by ECG or Holter 2 Age:18-75 years 3 Patients who are willing to enroll in the trial

Exclusion Criteria:

• 1 Patients accompanied hyperthyroidism 2 Patients with sever liver or renal dysfunction 3 Patients with sever cardiac dysfunction 4 Patients had previous radiofrequency catheter ablation in the LA or Maze surgical procedure 5 Patients with emboli in atrium 6 Pregnant woman